Abstract
Treatment of locally advanced non-small cell lung cancer (NSCLC) remains a significant challenge for oncologists, despite progress made in recent years in early diagnosis and therapy. This review focuses on integrated therapeutic approaches of patients with locally advanced NSCLC, summarizing the available evidence for patients with potentially resectable disease (stage IIIA-0/3) and with unresectable disease (stage IIIA-4/IIIB) and discussing several key questions related to the use of integrated approaches in NSCLC. Based on current evidence, neoadjuvant platinum-based combination chemotherapy is a treatment option in patients with potentially resectable stage IIIA-0/3: a 2-drug combination of platinum combined with a third-generation drug seems preferable, and at least 3 cycles of chemotherapy should be administered. There are no definitive evidences of clear superiority of surgery compared to radiotherapy for patients obtaining a response with neoadjuvant treatment: however, surgery is associated with a better local control, and subgroup analyses of randomized trials suggest improved outcome in patients in whom a complete resection could be obtained with a lobectomy, avoiding the increased surgical mortality associated with pneumonectomy. Standard treatment for patients with locally advanced, unresectable NSCLC is currently represented by combination of chemotherapy and radiotherapy. Concomitant approach has been proven superior to the sequential administration, although it is associated with higher risk of toxicity. All patients should be evaluated by a multidisciplinary team, skilled in multimodality treatment and should be counselled about risks and potential benefits of the different therapeutic approaches.
Keywords: Locally advanced NSCLC, multidisciplinary approach, combined treatment, chemotherapy, radiotherapy, surgery.
Anti-Cancer Agents in Medicinal Chemistry
Title:Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
Volume: 13 Issue: 6
Author(s): Massimo Di Maio, Raffaele Costanzo, Pasqualina Giordano, Maria Carmela Piccirillo, Claudia Sandomenico, Agnese Montanino, Guido Carillio, Paolo Muto, David R. Jones, Gennaro Daniele, Francesco Perrone, Gaetano Rocco and Alessandro Morabito
Affiliation:
Keywords: Locally advanced NSCLC, multidisciplinary approach, combined treatment, chemotherapy, radiotherapy, surgery.
Abstract: Treatment of locally advanced non-small cell lung cancer (NSCLC) remains a significant challenge for oncologists, despite progress made in recent years in early diagnosis and therapy. This review focuses on integrated therapeutic approaches of patients with locally advanced NSCLC, summarizing the available evidence for patients with potentially resectable disease (stage IIIA-0/3) and with unresectable disease (stage IIIA-4/IIIB) and discussing several key questions related to the use of integrated approaches in NSCLC. Based on current evidence, neoadjuvant platinum-based combination chemotherapy is a treatment option in patients with potentially resectable stage IIIA-0/3: a 2-drug combination of platinum combined with a third-generation drug seems preferable, and at least 3 cycles of chemotherapy should be administered. There are no definitive evidences of clear superiority of surgery compared to radiotherapy for patients obtaining a response with neoadjuvant treatment: however, surgery is associated with a better local control, and subgroup analyses of randomized trials suggest improved outcome in patients in whom a complete resection could be obtained with a lobectomy, avoiding the increased surgical mortality associated with pneumonectomy. Standard treatment for patients with locally advanced, unresectable NSCLC is currently represented by combination of chemotherapy and radiotherapy. Concomitant approach has been proven superior to the sequential administration, although it is associated with higher risk of toxicity. All patients should be evaluated by a multidisciplinary team, skilled in multimodality treatment and should be counselled about risks and potential benefits of the different therapeutic approaches.
Export Options
About this article
Cite this article as:
Maio Di Massimo, Costanzo Raffaele, Giordano Pasqualina, Piccirillo Carmela Maria, Sandomenico Claudia, Montanino Agnese, Carillio Guido, Muto Paolo, Jones R. David, Daniele Gennaro, Perrone Francesco, Rocco Gaetano and Morabito Alessandro, Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990076
DOI https://dx.doi.org/10.2174/18715206113139990076 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells
Current Molecular Medicine Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries
Current Cancer Therapy Reviews The Identification of a Novel Unsymmetrical Azine as an Apoptosis Inducer in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles
Current Medicinal Chemistry Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Assessment of Airway Inflammation by Exhaled Breath Condensate and Impedance Due to Gastroesophageal Reflux Disease (GERD)
Inflammation & Allergy - Drug Targets (Discontinued) Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Nano-Strategies for Improving the Bioavailability of Inhaled Pharmaceutical Formulations
Mini-Reviews in Medicinal Chemistry Aurora-B Kinase Inhibitors for Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening